Novartis confidently breaks out mid-stage data on Xolair competitor
Late last year, Novartis indicated its experimental therapy ligelizumab was Phase III ready after it outperformed Xolair — the company’s Roche-partnered chronic spontaneous urticaria therapy that has lost patent protection — in a Phase II study. On Tuesday, the Swiss drugmaker broke out some of the mid-stage data that triggered its confidence.
In the 382-patient trial, patients were either given ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab (Xolair) at a dose of 300 mg, or placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab. Patients in the study were already on antihistamines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.